Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Repligen's operating cash flow for the twelve months ending Sep 30, 2026 was $129.86M, down 0.8% year over year. For fiscal 2025 it was $117.42M, down 33.1% from the year before. Over ten years it grew 22.8% a year on average. The highest annual figure on record is $175.39M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.42M | -33.1% |
| FY2024 | Dec 31, 2024 | $175.39M | +54.0% |
| FY2023 | Dec 31, 2023 | $113.92M | -33.8% |
| FY2022 | Dec 31, 2022 | $172.08M | +44.6% |
| FY2021 | Dec 31, 2021 | $119.02M | +90.0% |
| FY2020 | Dec 31, 2020 | $62.63M | -6.8% |
| FY2019 | Dec 31, 2019 | $67.22M | +105.1% |
| FY2018 | Dec 31, 2018 | $32.77M | +87.8% |
| FY2017 | Dec 31, 2017 | $17.45M | +132.0% |
| FY2016 | Dec 31, 2016 | $7.52M | -50.0% |
| FY2015 | Dec 31, 2015 | $15.05M | -18.2% |
| FY2014 | Dec 31, 2014 | $18.40M | -29.0% |
| FY2013 | Dec 31, 2013 | $25.93M | +702.3% |
| FY2011 | Mar 31, 2011 | $3.23M | – |
| FY2010 | Mar 31, 2010 | -$2.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $43.10M | -10.4% |
| Q2 FY2026 | Jun 30, 2026 | $32.77M | +14.5% |
| Q1 FY2026 | Mar 31, 2026 | $28.30M | +88.6% |
| Q4 FY2025 | Dec 31, 2025 | $25.70M | -34.4% |
| Q3 FY2025 | Sep 30, 2025 | $48.10M | -2.5% |
| Q2 FY2025 | Jun 30, 2025 | $28.61M | -32.2% |
| Q1 FY2025 | Mar 31, 2025 | $15.01M | -66.4% |
| Q4 FY2024 | Dec 31, 2024 | $39.18M | +34.8% |
| Q3 FY2024 | Sep 30, 2024 | $49.32M | +25.7% |
| Q2 FY2024 | Jun 30, 2024 | $42.19M | +22.4% |
| Q1 FY2024 | Mar 31, 2024 | $44.71M | +300.8% |
| Q4 FY2023 | Dec 31, 2023 | $29.07M | -53.0% |
| Q3 FY2023 | Sep 30, 2023 | $39.23M | -5.2% |
| Q2 FY2023 | Jun 30, 2023 | $34.47M | -24.6% |
| Q1 FY2023 | Mar 31, 2023 | $11.15M | -51.7% |
| Q4 FY2022 | Dec 31, 2022 | $61.88M | +24.7% |
| Q3 FY2022 | Sep 30, 2022 | $41.37M | +84.0% |
| Q2 FY2022 | Jun 30, 2022 | $45.72M | +21.4% |
| Q1 FY2022 | Mar 31, 2022 | $23.11M | +149.5% |
| Q4 FY2021 | Dec 31, 2021 | $49.62M | +233.7% |
| Q3 FY2021 | Sep 30, 2021 | $22.48M | +4.6% |
| Q2 FY2021 | Jun 30, 2021 | $37.65M | +125.0% |
| Q1 FY2021 | Mar 31, 2021 | $9.26M | -2.8% |
| Q4 FY2020 | Dec 31, 2020 | $14.87M | -15.9% |
| Q3 FY2020 | Sep 30, 2020 | $21.49M | -2.2% |
| Q2 FY2020 | Jun 30, 2020 | $16.74M | -5.9% |
| Q1 FY2020 | Mar 31, 2020 | $9.53M | -2.6% |
| Q4 FY2019 | Dec 31, 2019 | $17.67M | +218.2% |
| Q3 FY2019 | Sep 30, 2019 | $21.97M | +11.6% |
| Q2 FY2019 | Jun 30, 2019 | $17.79M | +198.3% |
| Q1 FY2019 | Mar 31, 2019 | $9.79M | +522.6% |
| Q4 FY2018 | Dec 31, 2018 | $5.56M | -63.5% |
| Q3 FY2018 | Sep 30, 2018 | $19.68M | – |
| Q2 FY2018 | Jun 30, 2018 | $5.96M | +111.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.57M | +37.1% |
| Q4 FY2017 | Dec 31, 2017 | $15.22M | +678.8% |
| Q3 FY2017 | Sep 30, 2017 | -$1.73M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.15M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.95M | – |
See a number that looks wrong?